Insulin resistance and the renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension

Current Hypertension Reviews

Volumn 6, Issue 2, 2010, Pages 100-103

  Kamide, Kei ^a   Rakugi, Hiromi ^a   Ogihara, Toshio ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

Atherosclerosis; Insulin resistance; Oxidative stress; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; REACTIVE OXYGEN METABOLITE; RENIN;

ARTICLE; ATHEROSCLEROSIS; CELL GROWTH; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IN VIVO STUDY; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NEOVASCULARIZATION (PATHOLOGY); OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

EID: 77952485520     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340210791170976     Document Type: Article

References (23)

1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 289(19): 2570-72.
2. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011-53.
3. Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32; 3-107.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-53.
5. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995-03.
6. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-31.
7. Ogihara T, Nakao K, Fukui T, et al. Takao Saruta for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51(2): 393-398.
8. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12(Pt 3): 205S-213S.
9. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4(2): 51-61.
10. Kamide K, Hori MT, Zhu J-H, Barrett JD, Eggena P, Tuck ML. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998; 32(3): 482-87.
11. Kamide K, Hori MT, Zhu J-H, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18(8): 1051-56.
12. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004; 22(9): 1779-85.
13. Nickenig G, Röling J, Strehlow K, Schnabel P, Böhm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98(22): 2453-60.
14. Kamide K, Rakugi H, Nagai M, et al. Insulin-mediated modulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004; 22(1): 121-7.
15. Maeda N, Shimomura I, Kishida K. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8(7): 731-37.
16. Sharma AM, Janke K, Gorzelniak K, Engeli S, Luft EC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002; 40(5): 609-11.
17. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the reninangiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22(10): 1977-82.
18. Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100(9): 2158-69.
19. Gardner CD, Eguchi S, Reynolds CM, Eguchi K, Frank GD, Motley ED. Hydrogen peroxide inhibits insulin signaling in vascular smooth muscle cells. Exp Biol Med 2003; 228(7): 836-42.
20. Kamide K, Nagano M, Nakano N, et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996; 9(12 Pt 1): 1165-71.
21. Kamide, K, Rakugi H, Nakano N, et al. Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. Am J Hypertens 1997; 10(11): 1245-49.
22. Matayoshi T, Kamide K, Takiuchi S, et al. Relationship between insulin resistance and the renin-angiotensin system: analysis for patients with essential and renovascular hypertension. Clin Exp Hypertens 2007; 29(7): 479-87.
23. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48(2): 239-45.